Monoclonal antibodies directed against immune checkpoints including CTLA-4, PD1 or PD-L1 were found to be effective at potentiating radiotherapy, leading to enhanced primary responses and abscopal systemic responses in tumor models in mice [25, 48, 52, 54]. This evidence concerns the gene CD274 and neoplasm.